Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation.
Animals
Calcium Channel Blockers
/ administration & dosage
Cell Line
Databases, Factual
Drosophila
Drug Delivery Systems
/ methods
Female
Flunarizine
/ administration & dosage
Mice
Mice, Transgenic
Organ Culture Techniques
Poly(A)-Binding Protein I
/ antagonists & inhibitors
Prion Diseases
/ drug therapy
Prion Proteins
/ antagonists & inhibitors
Protein Aggregates
/ drug effects
Protein Folding
/ drug effects
Sheep
OPMD
PABPN1
PFAR
PrPSc
Prions
drug repositioning
Journal
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
ISSN: 1878-7479
Titre abrégé: Neurotherapeutics
Pays: United States
ID NLM: 101290381
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
accepted:
13
12
2020
pubmed:
4
2
2021
medline:
3
2
2022
entrez:
3
2
2021
Statut:
ppublish
Résumé
Prion diseases are caused by the propagation of PrP
Identifiants
pubmed: 33533011
doi: 10.1007/s13311-020-00992-6
pii: 10.1007/s13311-020-00992-6
pmc: PMC8423950
doi:
Substances chimiques
Calcium Channel Blockers
0
PABPN1 protein, mouse
0
Poly(A)-Binding Protein I
0
Prion Proteins
0
Protein Aggregates
0
Flunarizine
R7PLA2DM0J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1137-1150Informations de copyright
© 2021. The American Society for Experimental NeuroTherapeutics, Inc.
Références
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216(4542):136-44. https://doi.org/10.1126/science.6801762 .
doi: 10.1126/science.6801762
pubmed: 6801762
Bach S, Talarek N, Andrieu T, et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003;21(9):1075-81.
doi: 10.1038/nbt855
pubmed: 12910243
Nguyen P, Oumata N, Soubigou F, et al. Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. Eur J Med Chem 2014;82:363-71. https://doi.org/10.1016/j.ejmech.2014.05.083 .
doi: 10.1016/j.ejmech.2014.05.083
pubmed: 24927056
Nguyen PH, Hammoud H, Halliez S, et al. Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost alpha2-adrenergic receptor agonistic activity. ACS Chem Neurosci 2014;5(10):1075-82. https://doi.org/10.1021/cn5001588 .
doi: 10.1021/cn5001588
pubmed: 25244284
Oumata N, Nguyen PH, Beringue V, et al. The toll-like receptor agonist imiquimod is active against prions. PLoS One 2013;8(8):e72112. https://doi.org/10.1371/journal.pone.0072112.PONE-D-13-23175 .
doi: 10.1371/journal.pone.0072112.PONE-D-13-23175
pubmed: 23977222
pmcid: 3745460
Tribouillard-Tanvier D, Beringue V, Desban N, et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 2008;3(4):e1981.
doi: 10.1371/journal.pone.0001981
pubmed: 18431471
pmcid: 2291559
Voisset C, Saupe SJ, Galons H, Blondel M. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. Infect Disord Drug Targets 2009;9(1):31-9.
doi: 10.2174/1871526510909010031
pubmed: 19200013
Voisset C, Daskalogianni C, Contesse MA, et al. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus. Dis Model Mech 2014;7(4):435-44. https://doi.org/10.1242/dmm.014308 .
doi: 10.1242/dmm.014308
pubmed: 24558096
pmcid: 3974454
Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ, Blondel M. Tools for the study of ribosome-borne protein folding activity. Biotechnol J 2008;3(8):1033-40. https://doi.org/10.1002/biot.200800134 .
doi: 10.1002/biot.200800134
pubmed: 18683165
Voisset C, Blondel M, Jones GW, et al. The double life of the ribosome: When its protein folding activity supports prion propagation. Prion 2017;11(2):89-97. https://doi.org/10.1080/19336896.2017.1303587 .
doi: 10.1080/19336896.2017.1303587
pubmed: 28362551
pmcid: 5399909
Chattopadhyay S, Pal S, Pal D, et al. Protein folding in Escherichia coli: role of 23S ribosomal RNA. Biochim Biophys Acta 1999;1429(2):293-8.
doi: 10.1016/S0167-4838(98)00179-4
pubmed: 9989214
Das D, Das A, Samanta D, et al. Role of the ribosome in protein folding. Biotechnol J 2008;3(8):999-1009. https://doi.org/10.1002/biot.200800098 .
doi: 10.1002/biot.200800098
pubmed: 18702035
Ben-Shem A, Garreau de Loubresse N, Melnikov S, et al. The structure of the eukaryotic ribosome at 3.0 A resolution. Science 2011;334(6062):1524-9. https://doi.org/10.1126/science.1212642 .
doi: 10.1126/science.1212642
pubmed: 22096102
Tribouillard-Tanvier D, Dos Reis S, Gug F, et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 2008; 3(5):e2174.
doi: 10.1371/journal.pone.0002174
pubmed: 18478094
pmcid: 2374897
Blondel M, Soubigou F, Evrard J, et al. Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. Sci Rep 2016;6:32117. https://doi.org/10.1038/srep32117 .
doi: 10.1038/srep32117
pubmed: 27633137
pmcid: 5025663
Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nat Rev Genet 2018;19(7):405-18. https://doi.org/10.1038/s41576-018-0011-4 .
doi: 10.1038/s41576-018-0011-4
pubmed: 29713012
Gidaro T, Negroni E, Perie S, et al. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J Neuropathol Exp Neurol 2013;72(3):234-43. https://doi.org/10.1097/NEN.0b013e3182854c07 .
doi: 10.1097/NEN.0b013e3182854c07
pubmed: 23399899
Tome FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 1980;49(1):85-7. https://doi.org/10.1007/bf00692226 .
doi: 10.1007/bf00692226
pubmed: 6243839
Brais B, Bouchard J-P, Xie Y-G, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998;18:164-7.
doi: 10.1038/ng0298-164
pubmed: 9462747
Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998;18(2):164-7. https://doi.org/10.1038/ng0298-164 .
doi: 10.1038/ng0298-164
pubmed: 9462747
Jouan L, Rocheford D, Szuto A, et al. An 18 alanine repeat in a severe form of oculopharyngeal muscular dystrophy. Can J Neurol Sci 2014;41(4):508-11. https://doi.org/10.1017/s0317167100018588 .
doi: 10.1017/s0317167100018588
pubmed: 24878479
Richard P, Trollet C, Gidaro T, et al. PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling. J Neuromuscul Dis 2015; 2(2):175-80. https://doi.org/10.3233/JND-140060 .
doi: 10.3233/JND-140060
pubmed: 27858728
pmcid: 5271460
Barbezier N, Chartier A, Bidet Y, et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med 2011; 3(1):35-49. https://doi.org/10.1002/emmm.201000109 .
doi: 10.1002/emmm.201000109
pubmed: 21204267
pmcid: 3044817
Malerba A, Roth F, Harish P, et al. Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. Hum Mol Genet 2019. https://doi.org/10.1093/hmg/ddz007 .
Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem 2004; 47(6):1303-14.
doi: 10.1021/jm030480f
pubmed: 14998318
Wermuth CG. Multitargeted drugs: the end of the "one-target-one-disease" philosophy? Drug Discov Today 2004; 9(19):826-7.
doi: 10.1016/S1359-6446(04)03213-1
pubmed: 15381132
Kavitha CN, Kaur M, Jasinski JP, Yathirajan HS. Flunarizinium isonicotinate. Acta Crystallogr Sect E Struct Rep Online 2014; 70(Pt 6):o681-2. https://doi.org/10.1107/S1600536814010423 .
doi: 10.1107/S1600536814010423
pubmed: 24940261
pmcid: 4051108
Archer F, Bachelin C, Andreoletti O, et al. Cultured peripheral neuroglial cells are highly permissive to sheep prion infection. J Virol 2004; 78(1):482-90.
doi: 10.1128/JVI.78.1.482-490.2004
pubmed: 14671128
pmcid: 303391
Feraudet C, Morel N, Simon S, et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 2005; 280(12):11247-58. https://doi.org/10.1074/jbc.M407006200 .
doi: 10.1074/jbc.M407006200
pubmed: 15618225
Vilotte JL, Soulier S, Essalmani R, et al. Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp. J Virol 2001; 75(13):5977-84.
doi: 10.1128/JVI.75.13.5977-5984.2001
pubmed: 11390599
pmcid: 114313
Le Dur A, Beringue V, Andreoletti O, et al. A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes. Proc Natl Acad Sci U S A 2005;102(44):16031-6. 0502296102. https://doi.org/10.1073/pnas.0502296102 .
doi: 10.1073/pnas.0502296102
pubmed: 16239348
pmcid: 1276041
Langevin C, Andreoletti O, Le Dur A, Laude H, Beringue V. Marked influence of the route of infection on prion strain apparent phenotype in a scrapie transgenic mouse model. Neurobiol Dis 2011; 41(1):219-25. S0969-9961(10)00311-6. https://doi.org/10.1016/j.nbd.2010.09.010 .
doi: 10.1016/j.nbd.2010.09.010
pubmed: 20875860
Hasin N, Cusack SA, Ali SS, Fitzpatrick DA, Jones GW. Global transcript and phenotypic analysis of yeast cells expressing Ssa1, Ssa2, Ssa3 or Ssa4 as sole source of cytosolic Hsp70-Ssa chaperone activity. BMC Genomics 2014;15:194. https://doi.org/10.1186/1471-2164-15-194 .
doi: 10.1186/1471-2164-15-194
pubmed: 24628813
pmcid: 4022180
Parsell DA, Kowal AS, Lindquist S. Saccharomyces cerevisiae Hsp104 protein. Purification and characterization of ATP-induced structural changes. J Biol Chem 1994;269(6):4480-7.
doi: 10.1016/S0021-9258(17)41804-7
pubmed: 8308017
Falsig J, Aguzzi A. The prion organotypic slice culture assay--POSCA. Nat Protoc 2008;3(4):555-62. https://doi.org/10.1038/nprot.2008.13 .
doi: 10.1038/nprot.2008.13
pubmed: 18388937
Raz V, Routledge S, Venema A, et al. Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein. Am J Pathol 2011;179(4):1988-2000. https://doi.org/10.1016/j.ajpath.2011.06.044 .
doi: 10.1016/j.ajpath.2011.06.044
pubmed: 21854744
pmcid: 3181361
Chartier A, Klein P, Pierson S, et al. Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis. PLoS Genet 2015;11(3):e1005092. https://doi.org/10.1371/journal.pgen.1005092 .
doi: 10.1371/journal.pgen.1005092
pubmed: 25816335
pmcid: 4376527
Amery WK. Brain hypoxia in migraine: pathophysiologic and therapeutic implications. J Cereb Blood Flow Metab 1982;2 Suppl 1:S62-5.
pubmed: 7045147
Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 1983;23(2):70-4.
doi: 10.1111/j.1526-4610.1983.hed2302070.x
pubmed: 6343298
Binnie CD, de Beukelaar F, Meijer JW, et al. Open dose-ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia 1985;26(5):424-8.
doi: 10.1111/j.1528-1157.1985.tb05674.x
pubmed: 3899624
Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;27(1):6-44. https://doi.org/10.2165/00003495-198427010-00002 .
doi: 10.2165/00003495-198427010-00002
pubmed: 6141044
Santi CM, Cayabyab FS, Sutton KG, et al. Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 2002;22(2):396-403.
doi: 10.1523/JNEUROSCI.22-02-00396.2002
pubmed: 11784784
pmcid: 6758663
Karapetyan YE, Sferrazza GF, Zhou M, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci U S A 2013;110(17):7044-9. https://doi.org/10.1073/pnas.1303510110 .
doi: 10.1073/pnas.1303510110
pubmed: 23576755
pmcid: 3637718
Kocisko DA, Baron GS, Rubenstein R, et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 2003; 77(19):10288-94.
doi: 10.1128/JVI.77.19.10288-10294.2003
pubmed: 12970413
pmcid: 228499
Srivastava KR, Lapidus LJ. Prion protein dynamics before aggregation. Proc Natl Acad Sci U S A 2017; 114(14):3572-7. https://doi.org/10.1073/pnas.1620400114 .
doi: 10.1073/pnas.1620400114
pubmed: 28320943
pmcid: 5389334
Kocisko DA, Morrey JD, Race RE, Chen J, Caughey B. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. J Gen Virol 2004; 85(Pt 8):2479-83. https://doi.org/10.1099/vir.0.80082-0 .
doi: 10.1099/vir.0.80082-0
pubmed: 15269390
Halliez S, Jaumain E, Huor A, et al. White blood cell-based detection of asymptomatic scrapie infection by ex vivo assays. PLoS One 2014;9(8):e104287. https://doi.org/10.1371/journal.pone.0104287 .
doi: 10.1371/journal.pone.0104287
pubmed: 25122456
pmcid: 4133197
Papamichael K, Delitheos B, Tiligada E. A subset of histamine receptor ligands improve thermotolerance of the yeast Saccharomyces cerevisiae. J Appl Microbiol 2013;114(2):492-501. https://doi.org/10.1111/jam.12055 .
doi: 10.1111/jam.12055
pubmed: 23121472
Klein P, Oloko M, Roth F, et al. Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing. Nucleic Acids Res 2016;44(22):10929-45. https://doi.org/10.1093/nar/gkw703 .
doi: 10.1093/nar/gkw703
pubmed: 27507886
pmcid: 5159528
Chartier A, Benoit B, Simonelig M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 2006;25(10):2253-62.
doi: 10.1038/sj.emboj.7601117
pubmed: 16642034
pmcid: 1462976
Anvar SY, t’Hoen PA, Venema A, et al. Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. Skelet Muscle 2011; 1(1):15. https://doi.org/10.1186/2044-5040-1-15 .
doi: 10.1186/2044-5040-1-15
pubmed: 21798095
pmcid: 3156638
Winkler J, Tyedmers J, Bukau B, Mogk A. Chaperone networks in protein disaggregation and prion propagation. J Struct Biol 2012;179(2):152-60. https://doi.org/10.1016/j.jsb.2012.05.002 .
doi: 10.1016/j.jsb.2012.05.002
pubmed: 22580344
Kamili C, Hemalatha E, Sowmya Kandoti H, et al. Evaluation of memory-enhancing effect of flunarizine on active avoidance in experimental model of Alzheimer’s disease through calcium homeostasis. Int J Green Pharm 2019;13(4):348-53. https://doi.org/10.22377/ijgp.v13i04.2706 .
doi: 10.22377/ijgp.v13i04.2706
Sapaly D, Dos Santos M, Delers P, et al. Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy. Sci Rep 2018; 8(1):2075. https://doi.org/10.1038/s41598-018-20219-1 .
doi: 10.1038/s41598-018-20219-1
pubmed: 29391529
pmcid: 5794986
Kwon YJ, Falk MJ, Bennett MJ. Flunarizine rescues reduced lifespan in CLN3 triple knock-out Caenorhabditis elegans model of batten disease. J Inherit Metab Dis 2017;40(2):291-6. https://doi.org/10.1007/s10545-016-9986-1 .
doi: 10.1007/s10545-016-9986-1
pubmed: 27766444
Williams A, Sarkar S, Cuddon P, et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol 2008;4(5):295-305. https://doi.org/10.1038/nchembio.79 .
doi: 10.1038/nchembio.79
pubmed: 18391949
pmcid: 2635566
Zhang L, Yu J, Pan H, et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A 2007;104(48):19023-8. https://doi.org/10.1073/pnas.0709695104 .
doi: 10.1073/pnas.0709695104
pubmed: 18024584
pmcid: 2141901